-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The disease burden of patients with psoriasis and the use of systemic immunosuppressants may increase the risk of adverse consequences of COVID-19 , but data are limited
.
Recently, a study published in J Allergy Clin Immunol described the characteristics of the course of COVID-19 in patients with psoriasis and identified factors related to hospitalization
Immune to COVID-19
Clinicians report confirmed/suspected psoriasis patients with COVID-19 through an international registry, the Psoriasis Patient Registry of COVID-19 Infection Results, Treatment and Epidemiology
.
Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization
Infect
As a result, of the patients reported by 374 clinicians from 25 countries, 71% of patients were receiving biological treatment, 18% were receiving non-biological treatment, and 10% were not receiving any systemic treatment for psoriasis
.
In total, 348 patients (93%) fully recovered from COVID-19 infection, 77 (21%) were hospitalized, and 9 (2%) died
In summary, the results of the study show that in this international case series of patients with moderate to severe psoriasis, the use of biological agents has a lower risk of hospitalization associated with COVID-19 than the use of non-biological system therapies; however, considering the potential The selection bias and unmeasured confounding factors require further investigation
.
Existing risk factors (old age, male, non-white, and comorbidities) are associated with higher hospitalization rates
Original source:
Satveer K Mahil, et al.
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study in this message
